Illumina Reshapes Board: Former FDA Chief Takes Chair, Activist Investor Joins

Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board of Directors1 4.

Keith Meister, founder and Chief Investment Officer of Corvex Management, will join Illumina's Board on March 28, 20251 4.

Stephen MacMillan, who joined the Board in June 2023, will retire ahead of the upcoming annual shareholder meeting4.

Dr. Gottlieb has served on Illumina's Board since 2020 and is a former Commissioner of the U.S. Food and Drug Administration4.

Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation in genomics4.

The board changes are aimed at driving profitable growth and enhancing shareholder value4 6.

Corvex Management, Keith Meister's hedge fund, owns approximately 1.7 million shares of Illumina1.

Illumina's stock rose 2.2% in premarket trading following the announcement of these changes1.

The appointments signal a renewed focus on expanding Illumina's role in shaping the field of genomics and accelerating revenue growth6.

These board changes come as Illumina faces challenges and seeks to enhance its strategic direction in the rapidly evolving genomics industry10.

Sources: